WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 407223
Description: CJ-463 is a potent ans selective uPA inhibitor. Treatment with CJ-463 resulted in a significant inhibition of primary tumor growth, with the highest efficacy seen in the 100 mg/kg group. Urokinase (uPA) plays a crucial role in carcinogenesis by facilitating tumor cell invasion and metastasis. CJ-463 may be a novel agent for treatment of lung cancer.
MedKoo Cat#: 407223
Chemical Formula: C21H27N5O6S
Exact Mass: 477.1682
Molecular Weight: 477.536
Elemental Analysis: C, 52.82; H, 5.70; N, 14.67; O, 20.10; S, 6.71
CJ-463 purity > 98% is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to firstname.lastname@example.org to inquire quote.
Synonym: CJ-463; CJ 463; CJ463.
IUPAC/Chemical Name: (S)-N-(4-carbamimidoylbenzyl)-3-hydroxy-2-((R)-3-hydroxy-2-((phenylmethyl)sulfonamido)propanamido)propanamide
InChi Key: ZNOKJHWJKULOGM-ZWKOTPCHSA-N
InChi Code: InChI=1S/C21H27N5O6S/c22-19(23)16-8-6-14(7-9-16)10-24-20(29)17(11-27)25-21(30)18(12-28)26-33(31,32)13-15-4-2-1-3-5-15/h1-9,17-18,26-28H,10-13H2,(H3,22,23)(H,24,29)(H,25,30)/t17-,18+/m0/s1
SMILES Code: N=C(C1=CC=C(CNC([C@@H](NC([C@@H](CO)NS(=O)(CC2=CC=CC=C2)=O)=O)CO)=O)C=C1)N
The following data is based on the product molecular weight 477.536 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Henneke I, Greschus S, Savai R, Korfei M, Markart P, Mahavadi P, Schermuly RT,
Wygrecka M, Stürzebecher J, Seeger W, Günther A, Ruppert C. Inhibition of
urokinase activity reduces primary tumor growth and metastasis formation in a
murine lung carcinoma model. Am J Respir Crit Care Med. 2010 Mar 15;181(6):611-9.
doi: 10.1164/rccm.200903-0342OC. Epub 2010 Jan 7. PubMed PMID: 20056905.